Pharmacy News Article

Oct 30, 2009 (Datamonitor via COMTEX) Interlace Medical, a medical device company, has received the FDA's 510(k) clearance to market the MyoSure hysteroscopic tissue removal system for the removal of submucosal fibroids and polyps.

The MyoSure system enables physicians to quickly remove fibroids in a single step, avoid risks associated with energy-based devices, and will provide women with an incision-less treatment alternative that preserves uterine form and function. The easy-to-use device provides gynecologists with confidence, control and a minimally invasive care option for their patients, Interlace Medical said.

Bill Gruber, president and CEO of Interlace medical, said: "An increasing number of gynecologists and their patients are choosing less invasive treatment options which preserve uterine form and function and fewer life interruptions. With the MyoSure system, a 3cm fibroid can be removed in less than 10 minutes.

"In addition, the MyoSure device's small outer diameter minimizes the need for cervical dilation often associated with other hysteroscopic procedures thereby reducing the risk of cervical perforation and trauma."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon